Meeting
2021 Genitourinary Cancers Symposium
Medication adherence among prostate cancer patients using advanced oral therapies.
Authors
Dominic Pilon
Analysis Group, Inc., Montreal, QC, Canada
Dominic Pilon , Joyce Lamori , Carmine Rossi , Isabelle Ghelerter , Xuehua Ke , Marie-Hélène Lafeuille , Patrick Lefebvre , Lorie Ellis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 44)
DOI
10.1200/JCO.2021.39.6_suppl.44
Abstract #
44
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.
First Author: Alicia K. Morgans
Poster
2018 Genitourinary Cancers Symposium
Phase II randomized study of abiraterone acetate plus ADT versus apalutamide versus abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels. (LACOG 0415).
First Author: Fernando C. Maluf
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan
Poster
2023 ASCO Genitourinary Cancers Symposium
Patient perceptions regarding the process of obtaining oral prostate cancer medications.
First Author: Eric B Schwartz